MTOR and neurofibromatosis type 1: Conversely, administration of (S)-1-[(3-chlorophenyl)sulfonyl]-4-(pyrrolidine-3-yl-amino)-1H-pyrrolo [3,2-c]quinolone (CPPQ), a 5-HT6 receptor neutral antagonist [21,33,34], does not induce any cognitive improvement, suggesting that mTOR under the control of constitutively active 5-HT6 receptors, contributes to cognitive symptoms of NF1.